Prof. Humaid Obaid Al-Shamsi is the Chief Executive Officer of Burjeel Cancer Institute in Abu Dhabi, UAE, President of the Emirates Oncology Society, Lead of the Gulf Cancer Society, Visiting Professor at Harvard Medical School at Harvard University, Full Professor of Oncology at the Ras Al Khaimah Medical and Health Sciences University, Ras Al Khaimah, UAE, and an Adjunct Professor of Oncology at the College of Medicine, University of Sharjah. He is the first Emirati to be promoted as a professor in oncology in the UAE. He is also the Chairman for Colorectal Cancer in the MENA region, appointed by the prestigious National Comprehensive Cancer Network® in the USA. He is also the only member of the Lung Cancer Policy Network in the MENA region that aims to advance lung cancer research and screening globally. He is the Chairman of the Oncology and Hematology Fellowship Training Program for the National Institute for Health Specialties in the United Arab Emirates. He is the only member in GCC in the WIN Consortium, which is comprised of organizations representing all stakeholders in personalized cancer medicine globally.

He is board-certified in both internal medicine and oncology from the UK, USA (ABIM), and Canada (FRCPC). He has also been awarded the FRCP (Canada) in 2012, FRCP (London) in 2023, and FRCP (Glasgow) in 2024. He is the only physician in the UAE with a subspecialty fellowship certification and training in gastrointestinal oncology and the first Emirati to train and complete a clinical post-doctoral fellowship in palliative care. He was an assistant professor at the University of Texas MD Anderson Cancer Center between 2014 and 2017. He has published more than 160 peer-reviewed articles in JAMA Oncology, Lancet Oncology, Journal of Clinical Oncology, The Oncologist, BMC Cancer, and many others. His area of expertise includes precision oncology and cancer care in the UAE. In 2016, he published with his group from MD Anderson at the Journal of Clinical Oncology a study describing a new distinct subgroup of colorectal cancer, NON-V600 BRAF-mutated colorectal cancer. In 2022, he published the first book about cancer research in the UAE and also the first book about cancer in the Arab world, both of which were launched at Dubai Expo 2020. Cancer in the Arab World has been downloaded more than 500,000 times in its first 2 years of publication and is the ultimate source of cancer data in the Arab region.

He also published the first comprehensive book, “Cancer Care in the United Arab Emirates,” which is the first book in UAE history to document the cancer care in the UAE with many topics addressed for the first time. The book was also another success with over 100,000 downloads in the first 2 months of publication. He is passionate about advancing cancer care in the UAE and the GCC and has made significant contributions to cancer awareness and early detection for the public using social media platforms. He is considered the most followed oncologist in the world, with over half a million subscribers across his social media platforms (Instagram, Twitter, LinkedIn, and TikTok). In 2022, he was awarded the prestigious Feigenbaum Leadership Excellence Award from Sheikh Hamdan Smart University for his exceptional leadership and research, and he was also awarded the Sharjah Award for Volunteering. He was also named the Researcher of the Year in the UAE in 2020 and 2021 by the Emirates Oncology Society.

In May 2024, HH Sheikh Mansour bin Zayed Al Nahyan, Vice President of the United Arab Emirates, awarded him first place in the Emirati Talent Competitiveness Council (NAFIS) program for outstanding leadership in the private sector across all business and medical disciplines. In Feb 2025, Prof. Al Shamsi was awarded the “Sheikha Fatima bint Mubarak Family Awards” for being a successful role model in UAE society.

As a CEO of Burjeel Cancer Institute, Prof. Al Shamsi is leading the largest cancer network in the UAE with over 30 oncologists and hematologists and built the first paediatric bone marrow transplant program in the UAE. He secured the UAE’s first European Society for Medical Oncology accreditation for a cancer center in the UAE at Burjeel Cancer Institute.

Beside his clinical and administrative duties, he is engaged in education and various levels of research training for medical trainees to enhance their clinical and research skills. He established the UAE’s first hematology and oncology fellowship training program accredited by the UAE National Institute for Health Specialties at Burjeel Cancer Institute.  His mission is to advance cancer care in the UAE and the MENA region and make cancer care accessible to everyone in need around the globe.

We are looking for collaboration with a multinational team of elite WIN Institutions in order to carry out meaningful clinical research for the benefit of our, and patients worldwide through cutting edge translational genomic studies.  We believe that by combing highest quality international research and clinical experiences from our unique group of patients, with others from around the world is a way to discover unique insights into the genetic causes and more effective treatment of human diseases.